📰 Human Use News
Page 89 - Human Use News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Human Use. Real-time updates on events, politics, business and more.
February 21, 2023
Upcoming Hearings - March 22 - Senate Committee on Health, Education, Labor and Pensions Hearing: “Taxpayers Paid Billions For It: So Why Would Moderna...
February 21, 2023
21.02.2023 - WAKIX (pitolisant) Net Revenue Increased ~41% Year-over-Year to $128.3 Million for Fourth Quarter 2022; ~43% to $437.9 Million for Full Year 2022 Achieved Net Income of $181.5 Million for Full Year 2022 Average Number of Patients on WAKIX ...
February 20, 2023
Pfizer’s COVID-19 vaccine contains mRNA fragments called “truncated mRNA.” This is a serious issue on top of the ...
February 20, 2023
Hemoglobinopathies market was valued at $4.2 billion in 2021, and is estimated to reach $7 billion by 2031, growing at a CAGR of 5.2% from 2022 to 2031.
February 20, 2023
The global Encephalitis Treatment Market is now assessed at US$ 20.14 billion in 2023, with a CAGR of 5.4% expected by 2033. Because to technology advancements in healthcare, the industry is expected to reach US$ 34.08 billion by 2033.The major factor attributing to the growth of the market is the high mortality and...
February 20, 2023
/PRNewswire/ -- Global biotechnology leader CSL (ASX: CSL) today announced that the European Commission has granted conditional marketing authorization (CMA)...
February 17, 2023
The first and only enzyme replacement therapy approved for alpha-mannosidosis in the US has been cleared for adult and paediatric patients.
February 16, 2023
A panel of the European Medicines Agency ((EMA)) converted the review of Pharming's (PHAR) drug leniolisib to standard review from accelerated assessment as the committee sent questions...
February 16, 2023
/PRNewswire/ -- Major players in the cervical cancer drugs market are F. Hoffmann-La Roche Ltd, Hetero, GlaxoSmithKline, Eli Lilly and Company, Pfizer, Alnylam...
February 15, 2023
SHELTON, CT / ACCESSWIRE / February 15, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal first quarter ending